Operating Segment Information and Concentrations of Risk - Operating Segments and Geographical Information (Parenthetical) (Detail) (USD $)
|
12 Months Ended | ||
---|---|---|---|
Mar. 31, 2015
|
Mar. 31, 2014
|
Mar. 31, 2013
|
|
Segment Reporting Information [Line Items] | |||
Research and development costs | $ 31,700,000us-gaap_ResearchAndDevelopmentExpense | $ 33,100,000us-gaap_ResearchAndDevelopmentExpense | $ 37,200,000us-gaap_ResearchAndDevelopmentExpense |
Selling, general and administrative expenses | 245,500,000us-gaap_SellingGeneralAndAdministrativeExpense | 224,400,000us-gaap_SellingGeneralAndAdministrativeExpense | 218,600,000us-gaap_SellingGeneralAndAdministrativeExpense |
Asset impairment | 16,900,000us-gaap_ImpairmentOfLongLivedAssetsHeldForUse | ||
Asbestos adjustments | (33,400,000)jhx_AsbestosAdjustments | 195,800,000jhx_AsbestosAdjustments | 117,100,000jhx_AsbestosAdjustments |
AICF SG&A expenses | 2,500,000jhx_AicfOperatingCostPaidNonClaimHandling | 2,100,000jhx_AicfOperatingCostPaidNonClaimHandling | 1,700,000jhx_AicfOperatingCostPaidNonClaimHandling |
Net interest (expense) income | (7,500,000)us-gaap_InterestIncomeExpenseNet | (1,100,000)us-gaap_InterestIncomeExpenseNet | 2,400,000us-gaap_InterestIncomeExpenseNet |
General Corporate [Member] | |||
Segment Reporting Information [Line Items] | |||
Asbestos adjustments |
33,400,000jhx_AsbestosAdjustments / us-gaap_StatementBusinessSegmentsAxis = jhx_GeneralCorporateMember |
(195,800,000)jhx_AsbestosAdjustments / us-gaap_StatementBusinessSegmentsAxis = jhx_GeneralCorporateMember |
(117,100,000)jhx_AsbestosAdjustments / us-gaap_StatementBusinessSegmentsAxis = jhx_GeneralCorporateMember |
Value of Asbestos-related assets |
657,300,000jhx_AsbestosRelatedAssetsValue / us-gaap_StatementBusinessSegmentsAxis = jhx_GeneralCorporateMember |
812,400,000jhx_AsbestosRelatedAssetsValue / us-gaap_StatementBusinessSegmentsAxis = jhx_GeneralCorporateMember |
|
USA & Europe Fiber Cement [Member] | |||
Segment Reporting Information [Line Items] | |||
Research and development costs |
6,100,000us-gaap_ResearchAndDevelopmentExpense / us-gaap_StatementBusinessSegmentsAxis = jhx_UnitedStatesOfAmericaAndEuropeFiberCementMember |
9,600,000us-gaap_ResearchAndDevelopmentExpense / us-gaap_StatementBusinessSegmentsAxis = jhx_UnitedStatesOfAmericaAndEuropeFiberCementMember |
11,900,000us-gaap_ResearchAndDevelopmentExpense / us-gaap_StatementBusinessSegmentsAxis = jhx_UnitedStatesOfAmericaAndEuropeFiberCementMember |
Asset impairment |
16,900,000us-gaap_ImpairmentOfLongLivedAssetsHeldForUse / us-gaap_StatementBusinessSegmentsAxis = jhx_UnitedStatesOfAmericaAndEuropeFiberCementMember |
||
Asia Pacific Fiber Cement [Member] | |||
Segment Reporting Information [Line Items] | |||
Research and development costs |
1,400,000us-gaap_ResearchAndDevelopmentExpense / us-gaap_StatementBusinessSegmentsAxis = jhx_AsiaPacificFiberCementMember |
1,300,000us-gaap_ResearchAndDevelopmentExpense / us-gaap_StatementBusinessSegmentsAxis = jhx_AsiaPacificFiberCementMember |
1,700,000us-gaap_ResearchAndDevelopmentExpense / us-gaap_StatementBusinessSegmentsAxis = jhx_AsiaPacificFiberCementMember |
Adjustments to provision for New Zealand product benefit / (expense) claims |
4,300,000us-gaap_ProductLiabilityAccrualPeriodExpense / us-gaap_StatementBusinessSegmentsAxis = jhx_AsiaPacificFiberCementMember |
(1,800,000)us-gaap_ProductLiabilityAccrualPeriodExpense / us-gaap_StatementBusinessSegmentsAxis = jhx_AsiaPacificFiberCementMember |
(13,200,000)us-gaap_ProductLiabilityAccrualPeriodExpense / us-gaap_StatementBusinessSegmentsAxis = jhx_AsiaPacificFiberCementMember |
Research and Development [Member] | |||
Segment Reporting Information [Line Items] | |||
Research and development costs |
24,200,000us-gaap_ResearchAndDevelopmentExpense / us-gaap_StatementBusinessSegmentsAxis = us-gaap_ResearchAndDevelopmentArrangementMember |
22,200,000us-gaap_ResearchAndDevelopmentExpense / us-gaap_StatementBusinessSegmentsAxis = us-gaap_ResearchAndDevelopmentArrangementMember |
23,600,000us-gaap_ResearchAndDevelopmentExpense / us-gaap_StatementBusinessSegmentsAxis = us-gaap_ResearchAndDevelopmentArrangementMember |
Selling, general and administrative expenses |
1,800,000us-gaap_SellingGeneralAndAdministrativeExpense / us-gaap_StatementBusinessSegmentsAxis = us-gaap_ResearchAndDevelopmentArrangementMember |
2,200,000us-gaap_SellingGeneralAndAdministrativeExpense / us-gaap_StatementBusinessSegmentsAxis = us-gaap_ResearchAndDevelopmentArrangementMember |
2,400,000us-gaap_SellingGeneralAndAdministrativeExpense / us-gaap_StatementBusinessSegmentsAxis = us-gaap_ResearchAndDevelopmentArrangementMember |
AICF Funding [Member] | |||
Segment Reporting Information [Line Items] | |||
Net interest (expense) income |
$ 1,400,000us-gaap_InterestIncomeExpenseNet / us-gaap_StatementBusinessSegmentsAxis = jhx_AsbestosInjuriesCompensationFundMember |
$ 2,900,000us-gaap_InterestIncomeExpenseNet / us-gaap_StatementBusinessSegmentsAxis = jhx_AsbestosInjuriesCompensationFundMember |
$ 7,000,000us-gaap_InterestIncomeExpenseNet / us-gaap_StatementBusinessSegmentsAxis = jhx_AsbestosInjuriesCompensationFundMember |
X | ||||||||||
- Definition
AICF operating cost paid non claim handling. No definition available.
|
X | ||||||||||
- Definition
Comprised of changes in actuarial estimates received as of March 31 each year and the effect of foreign exchange movements in the asbestos related assets and liabilities which are denominated in Australian dollars. No definition available.
|
X | ||||||||||
- Definition
Asbestos related assets value. No definition available.
|
X | ||||||||||
- Definition
The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
X | ||||||||||
- Definition
The net amount of operating interest income (expense). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
X | ||||||||||
- Definition
The amount of loss reported during the period pertaining to product liability. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
X | ||||||||||
- Definition
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
X | ||||||||||
- Details
|
X | ||||||||||
- Definition
The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|